Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended
Dec. 31, 2011
Dec. 31, 2010
REVENUES    
Neurometric Information Services $ 32,000 $ 27,300
Clinical Services 152,300 120,600
Sales Revenue, Services, Net 184,300 147,900
OPERATING EXPENSES    
Cost of neurometric services revenues 39,200 36,100
Research 69,700 211,000
Product development 112,500 144,400
Sales and marketing 330,000 246,700
General and administrative 1,061,300 1,053,800
Total operating expenses 1,612,700 1,692,000
OPERATING LOSS (1,428,400) (1,544,100)
OTHER INCOME (EXPENSE)    
Interest income (expense), net (1,482,000) (2,627,100)
Financing fees (45,300) (142,700)
Offering costs (6,800) 0
Gain on derivative liabilities 232,100 4,217,500
Total other income (1,302,000) 1,447,700
LOSS BEFORE INCOME TAXES (2,730,400) (96,400)
Income taxes 900 1,300
NET LOSS $ (2,731,300) $ (97,700)
NET LOSS PER SHARE:    
Basic (in dollars per share) $ (0.05) $ 0
Diluted (in dollars per share) $ (0.05) $ 0
WEIGHTED AVERAGE SHARES OUTSTANDING:    
Basic (in shares) 56,207,507 56,023,921
Diluted (in shares) 56,207,507 56,023,921